BGI Genomics Co., Ltd.

Equities

300676

CNE100003449

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. 06:00:00 2024-04-14 pm EDT 5-day change 1st Jan Change
39.02 CNY +0.98% Intraday chart for BGI Genomics Co., Ltd. -0.46% -18.71%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BGI Genomics' 2023 Profit Falls 89% as Revenue Plunges 38% MT
BGI Genomics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China stocks rise further on market rescue hopes; HK flat RE
Wuxi AppTec Denies Ties to Military in Wake of US Draft Bill Targeting Chinese Biotech Firms MT
US bill targeting Chinese biotech firms WuXi AppTec, BGI hits delay RE
Correction: GemPharmatech Responds to US Legislation Concerns MT
Correction: Chinese Shares End Lower on US Draft Bill Targeting Chinese Biotech Firms; MGI Slumps 12%, Wuxi AppTec Falls 9% MT
GemPharmatech Responds to US Legislation Concerns MT
MGI Tech Responds to US BIOSECURE Act MT
Chinese Shares End Lower on US Draft Bill Targeting Chinese Biotech Firms; MGI Slumps 12%, Wuxi AppTec Falls 9% MT
US House bill would curb genetic info sharing with China's Wuxi Apptec, BGI RE
BGI Genomics Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Chinese Shares Extend Losses as Bank Borrowing Plunges to 14-Year Low; BGI Falls 6% After M&A Announcement MT
BGI Genomics to Acquire Health Management Firm; Shares Slump 6% MT
BGI Genomics Co., Ltd. signed a share transfer agreement to acquire Shenzhen Huada Special Inspection Technology Co., Ltd. from Shenzhen BGI Hospital Management Holding Co., Ltd. for CNY 0.71 million. CI
BGI Genomics Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
BGI Genomics Appoints COO MT
BGI Genomics Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
BGI Genomics Co., Ltd. agreed to acquire 15.65% stake in BGI Shuji Biotechnology Co., Ltd. for CNY 55.2 million. CI
BGI Genomics Partners with Zentya to Launch Fecal DNA Test for Colorectal Cancer in Slovakia CI
China opposes U.S. adding Chinese firms to trade blacklist RE
US Adds BGI, Inspur to Trade Blacklist MT
US adds units of China's BGI, Inspur to trade blacklist RE
BGI Genomics Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Shenzhen Hemu Gene Biotechnology Co., Ltd. announced that it has received CNY 30 million in funding from BGI Genomics Co., Ltd. CI
Chart BGI Genomics Co., Ltd.
More charts
BGI Genomics Co., Ltd. is a leading provider of genomic and proteomic sequencing services primarily to academic institutions, pharmaceutical companies and healthcare providers. The company also provides genomic solutions for biomarker research and development, screening for some of the trisomies present at birth (trisomy 21, trisomy 18 and trisomy 13) and solutions for neo-antigen identification for immuno-oncology research.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 300676 Stock
  4. News BGI Genomics Co., Ltd.
  5. Market Chatter: BGI's Prenatal Test Developed With Chinese Military Harvests Gene Data